The Food and Drug Administration on Monday approved a new treatment for patients with advanced ovarian cancer — an antibody that delivers a targeted dose of chemotherapy directly to cancer cells.
The new drug, called Elahere, was developed by Immunogen, a biotech company based in Waltham, Mass. It’s the first new treatment option for advanced ovarian cancer to reach the U.S. market in more than seven years, and the first approval of a wholly owned medicine in Immunogen’s 41-year history.
The FDA approved Elahere to treat patients with advanced ovarian cancer no longer responsive to platinum-based chemotherapy. Tumors are also required to contain high levels of a protein called folate receptor alpha on their surface.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect